The EGFR inhibitors cetuximab, panitumumab and geftinib have been approved by FDA and are currently used for treatment of patients with lung cancer, and head and neck cancers (Blaszczak et al. 2017; Chong and Jänne 2013; Kazandjian et al. 2016). The gene discussed is EGFR; the disease is lung cancer.